Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapy company focused on oncology, has announced a conference call and webcast scheduled for Thursday, August 1, 2024, at 4:30 p.m. ET. The event will provide a corporate update and discuss financial results for the second quarter of 2024. Investors and interested parties can join via North American toll-free number (800) 836-8184 or international number (646) 357-8785, using conference ID 34386. A webcast will also be available on the company's Investor Relations page and archived for three months. A dial-in replay will be accessible for one week after the call.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), un'azienda di immunoterapia in fase clinica focalizzata sull'oncologia, ha annunciato una conferenza telefonica e una diretta web programmata per giovedì 1 agosto 2024, alle 16:30 ET. L'evento fornirà un aggiornamento aziendale e discuterà i risultati finanziari del secondo trimestre del 2024. Gli investitori e le parti interessate possono partecipare tramite il numero verde nordamericano (800) 836-8184 o il numero internazionale (646) 357-8785, utilizzando l'ID conferenza 34386. Sarà disponibile anche una diretta web sulla pagina delle Relazioni con gli Investitori della società, che sarà archiviata per tre mesi. Un replay telefonico sarà accessibile per una settimana dopo la chiamata.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), una empresa de inmunoterapia en etapa clínica centrada en oncología, ha anunciado una conferencia telefónica y una transmisión en línea programada para jueves 1 de agosto de 2024, a las 4:30 p.m. ET. El evento proporcionará una actualización corporativa y discutirá los resultados financieros del segundo trimestre de 2024. Los inversores y partes interesadas pueden unirse a través del número gratuito de América del Norte (800) 836-8184 o el número internacional (646) 357-8785, usando el ID de conferencia 34386. También estará disponible una transmisión en línea en la página de Relaciones con Inversores de la empresa, que se archivará durante tres meses. Una repetición por acceso telefónico estará disponible durante una semana después de la llamada.
온콜리틱스 바이오텍 주식회사 (NASDAQ: ONCY) (TSX: ONC)는 종양학에 집중하는 임상 단계 면역 치료 회사로, 2024년 8월 1일 목요일 오후 4시 30분 ET에 예정된 전화 회의 및 웹캐스트를 발표했습니다. 이 행사에서는 2024년 2분기 재무 결과에 대한 기업 업데이트 및 논의가 이루어질 것입니다. 투자자 및 관심 있는 당사자는 북미 무료 전화번호 (800) 836-8184 또는 국제 번호 (646) 357-8785으로 참여할 수 있으며, 회의 ID 34386을 사용해야 합니다. 또한 회사의 투자자 관계 페이지에서 웹캐스트를 이용할 수 있으며, 3개월 동안 아카이브됩니다. 전화 재생은 회의 후 1주일 동안 이용 가능합니다.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), une entreprise de biotechnologie en immunothérapie en phase clinique axée sur l'oncologie, a annoncé une conférence téléphonique et un webinaire prévus pour jeudi 1er août 2024, à 16h30 ET. L'événement fournira une Mise à jour de l'entreprise et discutera des résultats financiers du deuxième trimestre 2024. Les investisseurs et les parties intéressées peuvent se joindre via le numéro gratuit nord-américain (800) 836-8184 ou le numéro international (646) 357-8785, en utilisant l'ID de conférence 34386. Un webinaire sera également disponible sur la page des Relations avec les investisseurs de l'entreprise et archivé pendant trois mois. Une rediffusion par téléphone sera accessible pendant une semaine après l'appel.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), ein Unternehmen für Immuntherapie in der klinischen Phase, das sich auf Onkologie konzentriert, hat eine Telefonkonferenz und ein Webcast für Donnerstag, den 1. August 2024, um 16:30 Uhr ET angekündigt. Die Veranstaltung wird ein Unternehmensupdate und eine Diskussion der Finanzergebnisse für das zweite Quartal 2024 bieten. Investoren und interessierte Parteien können über die nordamerikanische gebührenfreie Nummer (800) 836-8184 oder die internationale Nummer (646) 357-8785 teilnehmen, indem sie die Konferenz-ID 34386 verwenden. Ein Webcast wird auch auf der Investor-Relations-Seite des Unternehmens verfügbar sein und für drei Monate archiviert. Eine Telefonwiederholung wird eine Woche nach dem Anruf zugänglich sein.
- None.
- None.
Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET
Conference Call & Webcast
Date: Thursday, August 1, 2024
Time: 4:30 p.m. ET
Dial In – North American Toll-Free: (800) 836-8184
Dial In – International: (646) 357-8785
RapidConnect: to join the conference call without operator assistance, please click here
Conference ID (if needed): 34386
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 660-6345 (
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Company Contact Jon Patton Director of IR & Communication | Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-917-679-9282 |
View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-second-quarter-financial-results-and-recent-operational-highlights-302204603.html
SOURCE Oncolytics Biotech® Inc.
FAQ
When is Oncolytics Biotech (ONCY) hosting its Q2 2024 earnings call?
How can investors access Oncolytics Biotech's (ONCY) Q2 2024 earnings call?
What will be discussed in Oncolytics Biotech's (ONCY) upcoming conference call?
How long will the replay of Oncolytics Biotech's (ONCY) Q2 2024 earnings call be available?
